Oppenheimer analyst Marcus Ho was not entirely surprised by the appointment of Paul Campanelli to President and CEO of Endo, noting that the company has been hit hard by the recent negative commentary surrounding opioids and the erosion in the generics pricing environment. The analyst points out that management reaffirmed Q3 and full-year 2016 guidance and is now directionally focused more on operational execution, with an emphasis on pipeline and paragraph IV opportunities on the generics side and product development on the branded side. He reiterates a Perform rating on the shares.